Shire PLC (LON:SHP) had its target price decreased by investment analysts at Goldman Sachs Group, Inc. (The) from GBX 6,800 ($88.59) to GBX 6,400 ($83.38) in a report issued on Wednesday, June 28th, Marketbeat Ratings reports. The brokerage currently has a “conviction-buy” rating on the biopharmaceutical company’s stock. Goldman Sachs Group, Inc. (The)’s price objective points to a potential upside of 50.15% from the company’s current price.
Other research analysts have also issued research reports about the stock. J P Morgan Chase & Co reissued an “overweight” rating on shares of Shire PLC in a research note on Tuesday, June 27th. Liberum Capital reissued a “hold” rating and issued a GBX 4,900 ($63.84) price objective on shares of Shire PLC in a research note on Wednesday, June 14th. Barclays PLC reissued an “overweight” rating and issued a GBX 6,300 ($82.07) price objective on shares of Shire PLC in a research note on Tuesday, June 27th. Deutsche Bank AG reaffirmed a “buy” rating and issued a GBX 6,300 ($82.07) target price on shares of Shire PLC in a report on Wednesday, May 3rd. Finally, BNP Paribas reaffirmed an “outperform” rating and issued a GBX 5,900 ($76.86) target price on shares of Shire PLC in a report on Wednesday, March 22nd. Three equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the stock. Shire PLC has a consensus rating of “Buy” and an average price target of GBX 6,024 ($78.48).
Shire PLC (LON SHP) traded down 2.03% during trading on Wednesday, reaching GBX 4262.50. 1,976,387 shares of the company were exchanged. The stock’s market capitalization is GBX 38.54 billion. The company’s 50-day moving average price is GBX 4,289.98 and its 200-day moving average price is GBX 4,559.16. Shire PLC has a 1-year low of GBX 4,025.00 and a 1-year high of GBX 5,377.00.
In related news, insider Dominic Blakemore bought 152 shares of the firm’s stock in a transaction on Friday, June 30th. The shares were bought at an average cost of GBX 4,255 ($55.43) per share, for a total transaction of £6,467.60 ($8,425.74).
Shire PLC Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.